In­ves­tiga­tive re­port calls for re­newed scruti­ny on Aca­dia drug; Im­bru­vi­ca fails in front­line DL­B­CL PhI­II

→ The spot­light on Aca­dia Phar­ma­ceu­ti­cals’ $ACAD Parkin­son’s drug has turned more in­tense as in­ves­tiga­tive jour­nal­ist Rod­dy Boyd (you might re­mem­ber his re­port­ing on Valeant) drops an ex­posé on the com­pa­ny. Fol­low­ing a se­ries of re­ports from CNN and ProP­ub­li­ca high­light­ing Nu­plazid’s dan­gers, Boyd’s ac­count pound­ed on both the con­tro­ver­sial his­to­ry of its ap­proval and its spot­ty safe­ty record since then.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER